- Home
- SUPN vs RCKT Comparison
SUPN vs RCKT Comparison
Compare SUPN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- RCKT
- Stock Information
- Founded
- SUPN 2005
- RCKT 1999
- Country
- SUPN United States
- RCKT United States
- Employees
- SUPN N/A
- RCKT N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- RCKT Health Care
- Exchange
- SUPN Nasdaq
- RCKT Nasdaq
- Market Cap
- SUPN 1.8B
- RCKT 264.0M
- IPO Year
- SUPN 2012
- RCKT N/A
- Fundamental
- Price
- SUPN $33.18
- RCKT $2.99
- Analyst Decision
- SUPN Hold
- RCKT Buy
- Analyst Count
- SUPN 2
- RCKT 13
- Target Price
- SUPN $36.00
- RCKT $18.50
- AVG Volume (30 Days)
- SUPN 790.6K
- RCKT 3.8M
- Earning Date
- SUPN 08-05-2025
- RCKT 08-04-2025
- Dividend Yield
- SUPN N/A
- RCKT N/A
- EPS Growth
- SUPN N/A
- RCKT N/A
- EPS
- SUPN 1.11
- RCKT N/A
- Revenue
- SUPN $667,997,000.00
- RCKT N/A
- Revenue This Year
- SUPN N/A
- RCKT N/A
- Revenue Next Year
- SUPN $12.02
- RCKT N/A
- P/E Ratio
- SUPN $29.94
- RCKT N/A
- Revenue Growth
- SUPN 11.82
- RCKT N/A
- 52 Week Low
- SUPN $26.65
- RCKT $2.19
- 52 Week High
- SUPN $40.28
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- SUPN 60.49
- RCKT 45.55
- Support Level
- SUPN $31.35
- RCKT $2.76
- Resistance Level
- SUPN $33.80
- RCKT $3.24
- Average True Range (ATR)
- SUPN 0.92
- RCKT 0.19
- MACD
- SUPN 0.16
- RCKT 0.17
- Stochastic Oscillator
- SUPN 79.12
- RCKT 74.85
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.